|
|
Vaccine Detail
|
BCG and Corynebacterium parvum for malignant melanoma |
| Vaccine Information |
- Vaccine Name: BCG and Corynebacterium parvum for malignant melanoma
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007587
- Type: Live, attenuated vaccine
- Status: Clinical trial
- Antigen: T-cell dependent
- Immunization Route: Intramuscular injection (i.m.)
- Description: used in both studies and administered by the Tine technique (36 prongs intrademal) into both axillac and groin areas at a dose of 3x10^8 live organisms per treatment; given weekly for 4 weeks, then every 2 weeks for four doeses, then every month for 6 months and finally every 2 months (Lipton et al., 1991).
|
| Host Response |
|
|
| References |
Lipton et al., 1991: Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991; 9(7); 1151-1156. [PubMed: 2045856].
|
|
